The most quietly radical development in liver medicine right now isn’t a new drug class—it’s the growing willingness to let algorithms get inside the messy parts of diagnosis and trial design. When artificial intelligence moves from “assistive tool” to “measurement standard,” it changes not just how clinicians interpret liver disease, but how the entire system decides what counts as progress. Metabolic dysfunction–associated steatohepatitis, often discussed under its evolving acronym landscape (MASH, formerly tied to nonalcoholic fatty liver disease naming), sits at the center of this shift. The disease is fueled by fat accumulation in the liver, which can spiral into (Read more…)
Lesen Sie den vollständigen Artikel auf Papierkugel - All About Everything.